Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Adamas Pharmaceuticals, Inc. ADMS
$8.22
На 18:00, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
0.00000000
-
week52high
9.15
-
week52low
4.02
-
Revenue
74461000
-
P/E TTM
-5
-
Beta
2.81558400
-
EPS
0.00000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 ноя 2021 г. в 05:00
Описание компании
Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. It is also developing ADS-5102 that is in Phase III clinical study to treat walking impairment in patients with multiple sclerosis and other indications; and ADS-4101, which has completed two Phase I studies for treating partial onset seizures in patients with epilepsy. In addition, the company offers Namzaric (memantine hydrochloride extended release and donepezil hydrochloride) capsules for the treatment of moderate to severe dementia of an Alzheimer's type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Piper Sandler | Neutral | Overweight | 12 окт 2021 г. |
| JMP Securities | Market Perform | Market Outperform | 12 окт 2021 г. |
| HC Wainwright & Co. | Neutral | Buy | 12 окт 2021 г. |
| William Blair | Market Perform | Outperform | 11 окт 2021 г. |
| HC Wainwright & Co. | Buy | Buy | 07 июн 2021 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| BIGHAM MICHAEL | D | 0 | 10000 | 24 ноя 2021 г. |
| BIGHAM MICHAEL | D | 0 | 10000 | 24 ноя 2021 г. |
| MAHONEY DAVID L | D | 0 | 10000 | 24 ноя 2021 г. |
| MAHONEY DAVID L | D | 0 | 112781 | 24 ноя 2021 г. |
| MacPhee John A | D | 0 | 10000 | 24 ноя 2021 г. |
| MacPhee John A | D | 0 | 202000 | 24 ноя 2021 г. |
| DEMSKI MARTHA J | D | 0 | 10000 | 24 ноя 2021 г. |
| DEMSKI MARTHA J | D | 0 | 5000 | 24 ноя 2021 г. |
| RICHO ANNA | D | 0 | 10000 | 24 ноя 2021 г. |
| RICHO ANNA | D | 0 | 25000 | 24 ноя 2021 г. |
Новостная лента
Lab-grown diamond maker Adamas One raises $11 mln in IPO
Market Watch
09 дек 2022 г. в 08:10
Adamas One Corp. JEWL, said it priced 2.45 million shares at $4.50 a share for proceeds of $11 million in its initial public offering for trading on Friday on the Nasdaq. The Scottsdale, Ariz.